Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques

Show simple item record

dc.contributor.author Kusi, Kwadwo A
dc.contributor.author Remarque, Edmond J
dc.contributor.author Riasat, Vanessa
dc.contributor.author Walraven, Vanessa
dc.contributor.author Thomas, Alan W
dc.contributor.author Faber, Bart W
dc.contributor.author Kocken, Clemens HM
dc.date.accessioned 2014-08-14T12:56:38Z
dc.date.available 2014-08-14T12:56:38Z
dc.date.issued 2011-07-04
dc.identifier.uri http://197.255.68.203/handle/123456789/5600
dc.description.abstract Abstract Background Increasing the breadth of the functional antibody response through immunization with Plasmodium falciparum apical membrane antigen 1 (PfAMA1) multi-allele vaccine formulations has been demonstrated in several rodent and rabbit studies. This study assesses the safety and immunogenicity of three PfAMA1 Diversity-Covering (DiCo) vaccine candidates formulated as an equimolar mixture (DiCo mix) in CoVaccine HT™ or Montanide ISA 51, as well as that of a PfAMA1-MSP119 fusion protein formulated in Montanide ISA 51. Methods Vaccine safety in rhesus macaques was monitored by animal behaviour observation and assessment of organ and systemic functions through clinical chemistry and haematology measurements. The immunogenicity of vaccine formulations was assessed by enzyme-linked immunosorbent assays and in vitro parasite growth inhibition assays with three culture-adapted P. falciparum strains. Results These data show that both adjuvants were well tolerated with only transient changes in a few of the chemical and haematological parameters measured. DiCo mix formulated in CoVaccine HT™ proved immunologically and functionally superior to the same candidate formulated in Montanide ISA 51. Immunological data from the fusion protein candidate was however difficult to interpret as four out of six immunized animals were non-responsive for unknown reasons. Conclusions The study highlights the safety and immunological benefits of DiCo mix as a potential human vaccine against blood stage malaria, especially when formulated in CoVaccine HT™, and adds to the accumulating data on the specificity broadening effects of DiCo mix.
dc.title Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques
dc.type Journal Article
dc.date.updated 2014-08-14T12:56:47Z
dc.description.version Peer Reviewed
dc.language.rfc3066 en
dc.rights.holder Kwadwo A Kusi et al.; licensee BioMed Central Ltd.


Files in this item

This item appears in the following Collection(s)

  • Immunology Department [184]
    The Department of Immunology conducts research in the field of immunology of infectious and non-infectious diseases. The Department has the overall goal of contributing knowledge to better diagnosis, management, control and prevention of infectious and non-infectious diseases in Ghana and worldwide. This is consistent with the overall strategy of the Noguchi Memorial Institute for Medical Research (NMIMR) and in line with the strategy of the College of Health Sciences of the University of Ghana.

Show simple item record

Search UGSpace


Browse

My Account